Antibody incidence and red blood cell transfusions in patients on daratumumab

Background Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2021-12, Vol.61 (12), p.3468-3472
Main Authors: Tauscher, Craig, Moldenhauer, Sheila, Bryant, Sandra, DiGuardo, Margaret, Jacob, Eapen K.
Format: Article
Language:English
Subjects:
Alloantibodies
Antibodies
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Blood
Blood transfusion
CD38 antigen
daratumamab
Erythrocyte Transfusion - adverse effects
Erythrocytes
Genotypes
Humans
Immunohematology
Immunotherapy
Incidence
Isoantibodies
Isoimmunization
Monoclonal antibodies
monoclonal antibody interference
Multiple Myeloma
Patients
Phenotypes
RBC alloimmunization
red blood cell transfusion
Targeted cancer therapy
Transfusion
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Daratumumab (Dara), an anti‐CD38 monoclonal antibody for hematologic malignancies, interferes with routine blood bank testing, specifically affecting the antibody screen and identification panels. In 2016, the AABB recommended performing a baseline phenotype or genotype before a patient (Pt) begins taking anti‐CD38 to avoid this interference and potential problems with transfusion. The objective of this study was to assess red blood cell (RBC) utilization and subsequent incidence of alloimmunization to the transfused RBCs in patients receiving Dara. Methods and Materials We monitored 244 patients taking Dara to determine their red blood cell transfusions and incidence of clinically significant antibody formation before and following administration of Dara. Poisson generalized estimating equations with log link were used comparing the post‐Dara incidence and prevalence to those prior, with significance defined as p 
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.16687